Tags

Type your tag names separated by a space and hit enter

Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials.
Pharmacopsychiatry 2015; 48(6):205-10P

Abstract

INTRODUCTION

Botulinum toxin A (BTA) injection into the glabellar region is currently being studied as a treatment for major depressive disorder (MDD). Here we explore efficacy data of this novel approach in a pooled analysis.

METHODS

A literature search revealed 3 RCTs on this topic. Individual patient data and clinical end points shared by these 3 trials were pooled and analyzed as one study (n=134) using multiple regression models with random effects.

RESULTS

In the pooled sample, the BTA (n=59) and the placebo group (n=75) did not differ in the baseline variables. Efficacy outcomes revealed BTA superiority over placebo: Improvement in the Hamilton Depression Rating Scale or Montgomery-Asberg Depression Rating Scale 6 weeks after baseline was 45.7% for BTA vs. 14.6% for placebo (p<0.0001), corresponding to a BTA response rate of 54.2% (vs. 10.7%) and a BTA remission rate of 30.5% (vs. 6.7%).

DISCUSSION

Equalling the status of a meta-analysis, this study increases evidence that a single treatment of BTA into the glabellar region can reduce symptoms of MDD. Further studies are needed to better understand how BTA exerts its mood-lifting effect.

Authors+Show Affiliations

Department of Psychiatry, University of Texas at Austin, Dell Medical School, Austin, TX, USA (MM).Department of Psychiatry, George Washington School of Medicine, USA.Department of Psychiatry, Social Psychiatry and Psychotherapy, Medical School Hannover, Germany (THCK, SJ).Department of Analytics, Seton Family of Hospitals, Austin, TX, USA (HR).Department of Dermatology, University of Texas at Austin, Dell Medical School, Austin, TX, USA (BHK, JSR).Department of Psychiatry, Social Psychiatry and Psychotherapy, Medical School Hannover, Germany (THCK, SJ).Department of Dermatology, University of Texas at Austin, Dell Medical School, Austin, TX, USA (BHK, JSR).Capital Clinical Research Associates, Rockville, MD, USA (NER).Asklepios Clinic North - Ochsenzoll, Asklepios Campus Hamburg, Medical Faculty, Semmelweis University, Germany (SJ, MAW).

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26252721

Citation

Magid, M, et al. "Treating Depression With Botulinum Toxin: a Pooled Analysis of Randomized Controlled Trials." Pharmacopsychiatry, vol. 48, no. 6, 2015, pp. 205-10.
Magid M, Finzi E, Kruger TH, et al. Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials. Pharmacopsychiatry. 2015;48(6):205-10.
Magid, M., Finzi, E., Kruger, T. H., Robertson, H. T., Keeling, B. H., Jung, S., ... Wollmer, M. A. (2015). Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials. Pharmacopsychiatry, 48(6), pp. 205-10. doi:10.1055/s-0035-1559621.
Magid M, et al. Treating Depression With Botulinum Toxin: a Pooled Analysis of Randomized Controlled Trials. Pharmacopsychiatry. 2015;48(6):205-10. PubMed PMID: 26252721.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials. AU - Magid,M, AU - Finzi,E, AU - Kruger,T H C, AU - Robertson,H T, AU - Keeling,B H, AU - Jung,S, AU - Reichenberg,J S, AU - Rosenthal,N E, AU - Wollmer,M A, Y1 - 2015/08/07/ PY - 2015/8/8/entrez PY - 2015/8/8/pubmed PY - 2016/6/4/medline SP - 205 EP - 10 JF - Pharmacopsychiatry JO - Pharmacopsychiatry VL - 48 IS - 6 N2 - INTRODUCTION: Botulinum toxin A (BTA) injection into the glabellar region is currently being studied as a treatment for major depressive disorder (MDD). Here we explore efficacy data of this novel approach in a pooled analysis. METHODS: A literature search revealed 3 RCTs on this topic. Individual patient data and clinical end points shared by these 3 trials were pooled and analyzed as one study (n=134) using multiple regression models with random effects. RESULTS: In the pooled sample, the BTA (n=59) and the placebo group (n=75) did not differ in the baseline variables. Efficacy outcomes revealed BTA superiority over placebo: Improvement in the Hamilton Depression Rating Scale or Montgomery-Asberg Depression Rating Scale 6 weeks after baseline was 45.7% for BTA vs. 14.6% for placebo (p<0.0001), corresponding to a BTA response rate of 54.2% (vs. 10.7%) and a BTA remission rate of 30.5% (vs. 6.7%). DISCUSSION: Equalling the status of a meta-analysis, this study increases evidence that a single treatment of BTA into the glabellar region can reduce symptoms of MDD. Further studies are needed to better understand how BTA exerts its mood-lifting effect. SN - 1439-0795 UR - https://www.unboundmedicine.com/medline/citation/26252721/Treating_depression_with_botulinum_toxin:_a_pooled_analysis_of_randomized_controlled_trials_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0035-1559621 DB - PRIME DP - Unbound Medicine ER -